AI Insights · Timothy · September 2022
Top 5 Medical Apps on iOS in Ireland, Q3 2022
In Q3 2022, the top 5 medical apps on iOS in Ireland showed varied performance trends in weekly downloads, revenue, and active users, according to Sensor Tower data.
In Q3 2022, the top 5 medical apps on iOS in Ireland exhibited diverse performance trends across weekly downloads, revenue, and active users, as reported by Sensor Tower. Here’s a closer look at how each app performed during this period.
Clarity: CBT Self Help Journal experienced fluctuating weekly revenue, peaking at approximately $756 in early September. Weekly downloads varied, reaching a high of 323 in late August, while active users saw a general upward trend, increasing from 343 in late June to 429 by the end of September.
Huckleberry: Baby & Child had a relatively steady weekly revenue, with notable peaks around $452 in mid-July and $411 in mid-September. Downloads saw minor fluctuations, peaking at 286 in mid-July. Active users showed a gradual increase, rising from 2.6K in late June to over 3.3K by the end of September.
FibriCheck displayed consistent weekly revenue, with slight variations and a peak of $369 in early July. Downloads remained stable, with a high of 272 in mid-July. Active users gradually increased from 309 in late June to 347 by the end of September.
SnoreLab: Record Your Snoring showed modest weekly revenue, with a peak of $171 in early July. Downloads were variable, peaking at 179 in mid-August. Active users saw minor fluctuations, maintaining around 392 for much of the quarter and ending at 312 in late September.
Complete Anatomy for iPad had varied weekly revenue, peaking at $280 in mid-September. Downloads were sporadic, with a notable peak of 32 in late September. Active users showed a significant increase, from 10 in early September to 54 by the end of the month.
These insights provide a snapshot of the performance trends for the top medical apps on iOS in Ireland during Q3 2022. For more detailed analysis and insights, visit Sensor Tower.